Investors

2023

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2016. OptiBiotix has made strong progress during this period in its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, wellbeing and pharmaceutical companies.

Highlights

• Successful placing to raise £1m from the placing of 1,282,051 new ordinary shares at 78p
• A substantive increase in IP portfolio which now covers 44 patents across 14 families, 8 strain registrations, and 7 trademarks
• Commercial agreement signed with KSF Acquisition UK Limited (brand owners of Slimfast)
• Commercial agreement signed with DSM
• Appointment of Professor Tim Spector to the Scientific Advisory Group
• Acquisition of skin Microbiome intellectual property and creation of a majority owned joint venture ('JV') called SkinBiotix Limited with The University of Manchester
• Second contract signed for the development of SweetBiotix®
• Strong scientific progress across its platform technologies including:-
  • The development of Microbiome modulators which can increase the growth rate and biological activity of specific microbial species in the human microbiome
  • The development of sweet natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies

Post-period end highlights

• New patent filing to protect combination ingredients to reduce cardiovascular risk factors
• Successful launch and sales of Slimbiome® in GoFigure® shakes and bars
• Appointment of Luis Gosalbez as Director of Business Development
• First products on the shelves in Whole Foods Market Inc.

Stephen O'Hara, CEO of OptiBiotix commented: "OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals. We are delighted to have GoFigure products containing SlimBiome on the shelves in a major retail chain with strong early sales and great customer feedback suggesting a high likelihood of success. I would like to thank our investors for their support, and look forward to an exciting and rewarding rest of 2016."

For further information, please contact:

2022

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2016. OptiBiotix has made strong progress during this period in its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, wellbeing and pharmaceutical companies.

Highlights

• Successful placing to raise £1m from the placing of 1,282,051 new ordinary shares at 78p
• A substantive increase in IP portfolio which now covers 44 patents across 14 families, 8 strain registrations, and 7 trademarks
• Commercial agreement signed with KSF Acquisition UK Limited (brand owners of Slimfast)
• Commercial agreement signed with DSM
• Appointment of Professor Tim Spector to the Scientific Advisory Group
• Acquisition of skin Microbiome intellectual property and creation of a majority owned joint venture ('JV') called SkinBiotix Limited with The University of Manchester
• Second contract signed for the development of SweetBiotix®
• Strong scientific progress across its platform technologies including:-
  • The development of Microbiome modulators which can increase the growth rate and biological activity of specific microbial species in the human microbiome
  • The development of sweet natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies

Post-period end highlights

• New patent filing to protect combination ingredients to reduce cardiovascular risk factors
• Successful launch and sales of Slimbiome® in GoFigure® shakes and bars
• Appointment of Luis Gosalbez as Director of Business Development
• First products on the shelves in Whole Foods Market Inc.

Stephen O'Hara, CEO of OptiBiotix commented: "OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals. We are delighted to have GoFigure products containing SlimBiome on the shelves in a major retail chain with strong early sales and great customer feedback suggesting a high likelihood of success. I would like to thank our investors for their support, and look forward to an exciting and rewarding rest of 2016."

For further information, please contact:

2021

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2016. OptiBiotix has made strong progress during this period in its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, wellbeing and pharmaceutical companies.

Highlights

• Successful placing to raise £1m from the placing of 1,282,051 new ordinary shares at 78p
• A substantive increase in IP portfolio which now covers 44 patents across 14 families, 8 strain registrations, and 7 trademarks
• Commercial agreement signed with KSF Acquisition UK Limited (brand owners of Slimfast)
• Commercial agreement signed with DSM
• Appointment of Professor Tim Spector to the Scientific Advisory Group
• Acquisition of skin Microbiome intellectual property and creation of a majority owned joint venture ('JV') called SkinBiotix Limited with The University of Manchester
• Second contract signed for the development of SweetBiotix®
• Strong scientific progress across its platform technologies including:-
  • The development of Microbiome modulators which can increase the growth rate and biological activity of specific microbial species in the human microbiome
  • The development of sweet natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies

Post-period end highlights

• New patent filing to protect combination ingredients to reduce cardiovascular risk factors
• Successful launch and sales of Slimbiome® in GoFigure® shakes and bars
• Appointment of Luis Gosalbez as Director of Business Development
• First products on the shelves in Whole Foods Market Inc.

Stephen O'Hara, CEO of OptiBiotix commented: "OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals. We are delighted to have GoFigure products containing SlimBiome on the shelves in a major retail chain with strong early sales and great customer feedback suggesting a high likelihood of success. I would like to thank our investors for their support, and look forward to an exciting and rewarding rest of 2016."

For further information, please contact:

2020

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2016. OptiBiotix has made strong progress during this period in its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, wellbeing and pharmaceutical companies.

Highlights

• Successful placing to raise £1m from the placing of 1,282,051 new ordinary shares at 78p
• A substantive increase in IP portfolio which now covers 44 patents across 14 families, 8 strain registrations, and 7 trademarks
• Commercial agreement signed with KSF Acquisition UK Limited (brand owners of Slimfast)
• Commercial agreement signed with DSM
• Appointment of Professor Tim Spector to the Scientific Advisory Group
• Acquisition of skin Microbiome intellectual property and creation of a majority owned joint venture ('JV') called SkinBiotix Limited with The University of Manchester
• Second contract signed for the development of SweetBiotix®
• Strong scientific progress across its platform technologies including:-
  • The development of Microbiome modulators which can increase the growth rate and biological activity of specific microbial species in the human microbiome
  • The development of sweet natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies

Post-period end highlights

• New patent filing to protect combination ingredients to reduce cardiovascular risk factors
• Successful launch and sales of Slimbiome® in GoFigure® shakes and bars
• Appointment of Luis Gosalbez as Director of Business Development
• First products on the shelves in Whole Foods Market Inc.

Stephen O'Hara, CEO of OptiBiotix commented: "OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals. We are delighted to have GoFigure products containing SlimBiome on the shelves in a major retail chain with strong early sales and great customer feedback suggesting a high likelihood of success. I would like to thank our investors for their support, and look forward to an exciting and rewarding rest of 2016."

For further information, please contact:

2019

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2016. OptiBiotix has made strong progress during this period in its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, wellbeing and pharmaceutical companies.

Highlights

• Successful placing to raise £1m from the placing of 1,282,051 new ordinary shares at 78p
• A substantive increase in IP portfolio which now covers 44 patents across 14 families, 8 strain registrations, and 7 trademarks
• Commercial agreement signed with KSF Acquisition UK Limited (brand owners of Slimfast)
• Commercial agreement signed with DSM
• Appointment of Professor Tim Spector to the Scientific Advisory Group
• Acquisition of skin Microbiome intellectual property and creation of a majority owned joint venture ('JV') called SkinBiotix Limited with The University of Manchester
• Second contract signed for the development of SweetBiotix®
• Strong scientific progress across its platform technologies including:-
  • The development of Microbiome modulators which can increase the growth rate and biological activity of specific microbial species in the human microbiome
  • The development of sweet natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies

Post-period end highlights

• New patent filing to protect combination ingredients to reduce cardiovascular risk factors
• Successful launch and sales of Slimbiome® in GoFigure® shakes and bars
• Appointment of Luis Gosalbez as Director of Business Development
• First products on the shelves in Whole Foods Market Inc.

Stephen O'Hara, CEO of OptiBiotix commented: "OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals. We are delighted to have GoFigure products containing SlimBiome on the shelves in a major retail chain with strong early sales and great customer feedback suggesting a high likelihood of success. I would like to thank our investors for their support, and look forward to an exciting and rewarding rest of 2016."

For further information, please contact:

2018

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2016. OptiBiotix has made strong progress during this period in its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, wellbeing and pharmaceutical companies.

Highlights

• Successful placing to raise £1m from the placing of 1,282,051 new ordinary shares at 78p
• A substantive increase in IP portfolio which now covers 44 patents across 14 families, 8 strain registrations, and 7 trademarks
• Commercial agreement signed with KSF Acquisition UK Limited (brand owners of Slimfast)
• Commercial agreement signed with DSM
• Appointment of Professor Tim Spector to the Scientific Advisory Group
• Acquisition of skin Microbiome intellectual property and creation of a majority owned joint venture ('JV') called SkinBiotix Limited with The University of Manchester
• Second contract signed for the development of SweetBiotix®
• Strong scientific progress across its platform technologies including:-
  • The development of Microbiome modulators which can increase the growth rate and biological activity of specific microbial species in the human microbiome
  • The development of sweet natural healthy sugars (SweetBiotix®) with safety and sweetness confirmed by human taste studies

Post-period end highlights

• New patent filing to protect combination ingredients to reduce cardiovascular risk factors
• Successful launch and sales of Slimbiome® in GoFigure® shakes and bars
• Appointment of Luis Gosalbez as Director of Business Development
• First products on the shelves in Whole Foods Market Inc.

Stephen O'Hara, CEO of OptiBiotix commented: "OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals. We are delighted to have GoFigure products containing SlimBiome on the shelves in a major retail chain with strong early sales and great customer feedback suggesting a high likelihood of success. I would like to thank our investors for their support, and look forward to an exciting and rewarding rest of 2016."

For further information, please contact: